LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections

BACKGROUND: SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, which are often severe and associated with substantial mortality. PPK, PTA, and clinical PK/PD analyses were conducted using all available PK and efficacy data to support SUL-DUR d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhavnani, Sujata M, Rubino, Christopher M, Hammel, Jeffrey P, Cammarata, Anthony P, Larson, Kajal, Liolios, Kathryn, McLeod, Sarah, Miller, Alita, Ambrose, Paul G, Tommasi, Ruben, O'Donnell, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752613/
http://dx.doi.org/10.1093/ofid/ofac492.1896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752613/
http://dx.doi.org/10.1093/ofid/ofac492.1896

Ejemplares similares